Q-omics provides the consensus-scored ADCY7 profile across patient tissues and cancer cell-line models. ADCY7 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ADCY7 is differentially expressed in 12, with the highest sampling consensus in KIRP. Additionally, ADCY7 RNA expression shows 19,038 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, KIRP, and LSCC as cancer lineages where ADCY7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADCY7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADCY7 survival associations across molecular data types. ADCY7 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADCY7 RNA expression–survival associations across cancer types. High ADCY7 expression shows unfavorable associations in MESO, UVM, CESC, BLCA and LUSC, but favorable associations in ESCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ADCY7 RNA expression.
This table summarizes ADCY7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ADCY7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADCY7 shows lower tumor expression in LUAD and higher tumor expression in KIRP, KIRC, HNSC, BLCA and STAD. The KIRP box plot shows higher ADCY7 RNA expression in tumor versus normal tissue (log2 FC = +1.629, t-test p < 0.001).
This table shows molecular features associated with ADCY7 in patient tissues and cancer cell lines. In patient samples, ADCY7 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ADCY7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
